FK739 | 133052-30-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: FK739
• 英文别名: 2-butyl-3-(2'-(1H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl)-methyl-3H-imidazo[4,5-b]pyridine；FK-739 free acid；2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine
• CAS: 133052-30-9
• 化学式: C₂₄H₂₃N₇
• 分子量: 409.494
• InChiKey: YILJWHUIUCRKEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  85.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4'-(2-n-butyl-3H-imidazo<4,5-b>pyridin-3-ylmethyl)biphenyl-2-carbonitrile 在 三甲基甲硅烷基锡 作用下， 以 甲苯 为溶剂， 反应 118.0h， 以69.5%的产率得到FK739
  参考文献：
  名称：

  一些N-取代的咪唑并吡啶衍生物的合成和结构分配

  摘要：

  描述了所有可能的N-烷基化的2-正丁基-咪唑并[4,5]吡啶异构体的合成及其通过1 H NMR谱的结构分配。这些衍生物中的一种，即2-正丁基-3- [2'-（1H-四唑-5-基）-4-联苯基甲基] -3H-咪唑并[4,5-b]吡啶9是有效的血管紧张素II受体拮抗剂。

  DOI：

  10.1016/s0040-4020(01)88351-4

文献信息

• Fused imidazole derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0434038A1

  公开（公告）日：1991-06-26

  Novel fused imidazole derivatives of the formula (I): wherein the ring A, which may be optionally substituted, is a six-membered heteroaromatic group having one or two hetero nitrogen atoms; R¹ is hydrogen or an alkyl, aralkyl or aryl group which may be optionally substituted; R² is hydrogen, halogen or nitro; R³ is a residue capable of forming an anion or a residue convertible into an anion; X is a direct bond or a spacer-having atomic length of two or less; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof have potent angiotensin II antagonist activity and hypotensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases, strokes, etc.

  新型融合的咪唑衍生物的化学式（I）：其中，环A是一个可能被取代的六元杂芳基团，具有一个或两个杂原子；R¹是氢或一个可以选择性取代的烷基、芳基或芳基烷基；R²是氢、卤素或硝基；R³是能够形成负离子的残基或可转化为负离子的残基；X是直接键或具有原子长度为两个或更少的间隔子；n是1或2的整数；其药学上可接受的盐具有强大的抗血管紧张素II活性和降压活性，因此可用作治疗循环系统疾病如高血压疾病、心脏疾病、中风等的治疗剂。
• Condensed imidazole derivatives and processes for preparation thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0426021A1

  公开（公告）日：1991-05-08

  A compound of the formula : wherein R¹ is lower alkyl, halo(lower)alkyl, cyclo(lower)alkyl or lower alkylthio, R² is hydrogen or imino-protective group, R³ is hydrogen or halogen, A is lower alkylene, and is a group of the formula : in which X¹, X², X³ and X⁴ are each N or CR⁴, in which R⁴ is hydrogen, lower alkyl, lower alkoxy, halogen, halo(lower)alkyl, esterified carboxy, halo(lower)alkoxy or hydroxy, provided that at least one of X¹, X², X³ and X⁴ is N, and pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising them as an active ingredient in admixture with a pharmaceutically acceptable carrier or excipient.

  该化合物的结构式如下：其中R¹为低碳烷基、卤代低碳烷基、环状低碳烷基或低碳硫代基，R²为氢或亚胺保护基，R³为氢或卤素，A为低碳烷基，是一个结构式中的基团：其中X¹、X²、X³和X⁴分别为N或CR⁴，其中R⁴为氢、低碳烷基、低碳氧基、卤素、卤代低碳烷基、酯化羧基、卤代低碳氧基或羟基，但至少其中一个为N，并且其药学上可接受的盐，以及其制备方法和包含它们作为活性成分与药学上可接受的载体或赋形剂混合的药物组合物。
• Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides
  申请人：Sedelmeier Gottfried

  公开号：US20070043098A1

  公开（公告）日：2007-02-22

  The present invention relates to a method for preparing substituted tetrazoles, compounds obtained according to this method, new reactants and new tetrazole derivatives.

  本发明涉及一种制备取代四氮唑的方法，根据该方法获得的化合物、新的反应物和新的四氮唑衍生物。
• PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES
  申请人：Sedelmeier Gottfried

  公开号：US20120330026A1

  公开（公告）日：2012-12-27

  The present invention relates to a method for preparing substituted tetrazoles, compounds obtained according to this method, new reactants and new tetrazole derivatives.

  本发明涉及一种制备取代四唑的方法，根据该方法获得的化合物，新的反应物和新的四唑衍生物。
• Biphenylmethane derivative, the use of it and pharmacological compositions containing same
  申请人：Eisai Co., Ltd.

  公开号：EP0420237A1

  公开（公告）日：1991-04-03

  The biphenylmethane derivative having the formula (I) is disclosed

  公开了具有式 (I) 的联苯甲烷衍生物